PE 22-28 vs Tesamorelin
Updated July 23, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of PE 22-28 and Tesamorelin (also searched as Tesamorelin vs PE 22-28) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
PE 22-28 centers on metabolic, while Tesamorelin leans toward metabolic. On indexed research, PE 22-28 is ahead (PE 22-28: 5 studies, Human evidence; Tesamorelin: 5, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •PE 22-28 is strongest for metabolic; Tesamorelin for metabolic.
- •Evidence: PE 22-28 Human evidence (5 studies) vs Tesamorelin Human clinical (5).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
TREK-1 Channel Blocker | Shortened Spadin Analog
GHRH Analog | Visceral Fat Reduction
PE 22-28 vs Tesamorelin: side-by-side
| Metric | PE 22-28 | Tesamorelin |
|---|---|---|
| Class | Cognitive | GH |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 5 | 5 |
| Research level | Emerging | FDA Approved |
| Strongest effect | Metabolic & appetite | Metabolic & appetite |
| Healing & recovery | 2.0▲ | 1.0 |
| Muscle & body comp | 0.0 | 2.0▲ |
| Metabolic & appetite | 4.0▲ | 4.0▲ |
| Neuro & mood | 3.0▲ | 1.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 2.0▲ | 1.0 |
| Skin & aesthetics | 0.0 | 3.0▲ |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | PE 22-28 | Tesamorelin |
|---|---|---|
| Mechanism | — | GHRH analog |
| Route | — | Subcutaneous injection |
| Half-life | — | ~26–38 min |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is PE 22-28?
### Summary PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.
Full PE 22-28 profile, mechanism & studies →What is Tesamorelin?
### Tesamorelin Summary Tesamorelin is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analog, primarily investigated for its potential to reduce visceral fat in individuals with HIV-associated lipodystrophy. Its role in metabolic health and body composition continues to be explored in various clinical contexts.
Full Tesamorelin profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | PE 22-28 | 2.0/5 effect signal |
| Muscle | Tesamorelin | 2.0/5 effect signal |
| Metabolic | Even | Both ~4.0/5 |
| Neuro | PE 22-28 | 3.0/5 effect signal |
| Inflammation | PE 22-28 | 2.0/5 effect signal |
| Skin | Tesamorelin | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack PE 22-28 and Tesamorelin?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
PE 22-28 vs Tesamorelin: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
PE 22-28 has 5 approved studies indexed (Human evidence), and Tesamorelin has 5 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is PE 22-28 or Tesamorelin better?
It depends on your goal. PE 22-28 is strongest for metabolic; Tesamorelin for metabolic. PE 22-28 has more indexed studies (5). See the goal-by-goal breakdown above.
Is PE 22-28 or Tesamorelin better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Is PE 22-28 or Tesamorelin better for muscle?
Tesamorelin leads on the muscle & body-composition axis (2.0/5).
Which has more research, PE 22-28 or Tesamorelin?
PE 22-28 has 5 approved studies indexed (Human evidence); Tesamorelin has 5 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack PE 22-28 and Tesamorelin?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of PE 22-28 vs Tesamorelin?
PE 22-28: no community-reported effects logged yet. Tesamorelin: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is PE 22-28 or Tesamorelin FDA-approved?
PE 22-28 is a research-use compound and is not FDA-approved. Tesamorelin is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Tesamorelin better than PE 22-28?
For metabolic, Tesamorelin has the edge; for metabolic, PE 22-28 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 23, 2026.